HIV protease inhibitors

Sunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned

Retrieved on: 
Wednesday, June 9, 2021
Protease inhibitor, Antiviral drugs, Draft:Sunshine Biopharma, Carbamates, Organofluorides, HIV protease inhibitors

The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.

Key Points: 
  • The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death.
  • Sunshine Biopharmas protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home.
  • We are moving the project forward as fast as possible, albeit within the constraints of science, said Dr. Steve Slilaty, CEO of Sunshine Biopharma.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

Retrieved on: 
Tuesday, November 3, 2020
Chemistry, Organic compounds, Chemical compounds, HIV protease inhibitors, Ureas, Hepatotoxins, Clinical Pharmacology & Therapeutics, Lopinavir, Favipiravir, Remdesivir, Clinical Pharmacology: Advances and Applications, Ritonavir

CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

Key Points: 
  • CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
  • We are honored to be sharing this peer-reviewed manuscript in an internationally acclaimed journal, said George Yeh, President of TLC.
  • CTS has a collection of clinical pharmacology research from various potential treatments such as remdesivir, favipiravir, and lopinavir/ritonavir.
  • Acknowledgment of our work by CTS further fortifies the soundness of our strategy of preferential delivery to the lungs.

Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients

Retrieved on: 
Wednesday, March 25, 2020
Health, RTT, Chemistry, Medicine, Hepatotoxins, HIV protease inhibitors, Carbamates, Ureas, Ritonavir, Hepatitis C, Clinical trial

HANGZHOUand SHAOXING,China, March 24, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv.

Key Points: 
  • HANGZHOUand SHAOXING,China, March 24, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv.
  • The data from this small-sample clinical study showed that danoprevir combined with ritonavir is safe and well tolerated in all patients.
  • Clinical findings suggest that danoprevir combined with ritonavir is a promising therapeutic option for COVID-19.
  • Ganovo (Danoprevir) is the first direct-acting anti-viral agent for hepatitis C, developed by a domestic firm in China.